Brian L. Wilson
Brian L. Wilson
Stop FollowingBrian L. Wilson
View as an RSS Feed
View Brian L. Wilson's Articles BY TICKER:
AAPL,
ABIO,
ABT,
ACAD,
ACHN,
ACRX,
AEGR,
AEZS,
AFFY,
ALXA,
AMPE,
AMRN,
AMZN,
ANAC,
ANTH,
APPA.OB,
APPY,
ARAY,
ARIA,
ARNA,
ARQL,
ARRY,
ASTX,
ATHX,
ATRS,
AVEO,
BAC,
BBRY,
BCRX,
BHP,
BIIB,
BLRX,
BMRN,
C,
CBMX,
CELG,
CHTP,
CLDX,
CLSN,
CORT,
CPRX,
CRME,
CUR,
CVM,
CYCC,
CYNO,
CYTK,
DARA,
DCTH,
DIS,
DMPI.OB,
DNDN,
DSCO,
DVAX,
EDAP,
EXEL,
F,
FOLD,
FRX,
FURX,
GALT,
GE,
GSK,
GWAY,
HALO,
HPTX,
HZNP,
IBM,
IMGN,
INO,
INTC,
ISIS,
ITMN,
JNJ,
JPM,
KERX,
KO,
LLY,
LNG,
LON,
LPTN,
LXRX,
MAKO,
MDVN,
MNKD,
MRK,
MSLP.OB,
MYRX,
NAVB,
NPSP,
NSPH,
NVS,
OMER,
ONCY,
ONXX,
OPXA,
ORCL,
OREX,
OSIR,
OSUR,
OXY,
PCRX,
PCYC,
PFE,
PGNX,
PPHM,
PTN,
QCOR,
REGN,
RIGL,
RMTI,
RPRX,
RPTP,
SCMP,
SDRL,
SGMO,
SKUL,
SLV,
SNGX.OB,
SPPI,
SPY,
SRPT,
STML,
STXS,
SUPN,
T,
THRX,
TKMR,
TLON.OB,
TTNP.OB,
VRTX,
VVUS,
WMT,
ZGNX,
ZIOP
- Amarin Reports Solid Vascepa TRx Growth, Stock Holds Its Ground
- Dendreon Shocks Market With Provenge Sales Decline In Q1
- Bracing For Dendreon Q1 2013 Earnings - All Eyes On Provenge
- Huge Potential But Tough Entry For Female Sexual Dysfunction Drugs
- Arena And Vivus Weaken On Poor Obesity Drug Prospects In Europe
- How Regeneron's Eylea Became A 'Trump Card' In The Niche AMD Market
- Ampio Pharma Initiates Phase III, Investors Extend Momentum
- Post-IPO Strength Seen In Stemline Therapeutics
- Galectin Therapeutics Gets A Bid After Promising Results
- FDA Rejects Titan Pharma's Opioid Addiction Implant Probuphine
- Questcor Pharmaceuticals In Play Ahead Of Earnings Release
- BioCryst Heats Up: H7N9 Virus Hits Taiwan, Fatalities Up Nearly 300%
- Renewed Buying Interest In Halozyme After Phase II Initiation
- Titan Pharma Approaches Expected FDA Approval
- Soligenix: Interesting Play In BioDefense Presenting At Today's Vaccine Expo
- Early-Stage Clinical Data Highlights From AACR 2013
- No NCE Decison For Amarin's Vascepa: The Launch Trudges Along
- Abbott: Galectin-3 Assay Sees Approval And Builds Takeover Case For La Jolla Pharmaceuticals
- MannKind's Afrezza Likely To Fail AFFINITY 1 Phase III Trial
- DelMar Pharmaceuticals: New, Promising Data For Glioblastoma Drug
- Muscular Dystrophy Drug Succeeds, Sarepta Buyers Flood In
- Questcor Set To Beat Wall Street Predictions
- BioCryst's Influenza Drug Brought Back From The Dead
- New Battleground Emerges For Dendreon Bulls And Bears
- Strength In Sucampo Heading Into FDA Decision And Analyst Activity
- Upcoming Trial Data May Help Salvage Bioline Rx
- Lucrative AMD And DME Markets Attract Wall Street To Regeneron And Other Players
- Promising RNA Company Tekmira Ready To Release Data At AACR 2013
- Tecfidera Raises The Bar For Biogen Idec
- Repros Moves Up On Phase III Data, Both Co-Endpoints Met
- Ziopharm's Palifosfamide Fails Its Soft Tissue Cancer Indication, NSCLC Next?
- Anacor Rallies On AN2728 Progress And Market Attention